Research ArticleIMMUNOTHERAPY

Tracking the fate and origin of clinically relevant adoptively transferred CD8+ T cells in vivo

See allHide authors and affiliations

Science Immunology  24 Feb 2017:
Vol. 2, Issue 8, eaal2568
DOI: 10.1126/sciimmunol.aal2568

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Tracking tumor immunity

Tumor-specific immune cells can lead to tumor regression in some cancer patients who do not respond to other therapies; however, the ability to track these cells after transfer has remained limited. Now, Chapuis et al. use high-throughput T cell receptor Vβ sequencing (HTTCS) to track individual clonotypes after transfer. They find that very low frequency clonotypes with proliferative and survival advantages can contribute to long-term tumor control. These data will help guide the selection of cell populations for immunotherapy.